Evidence map›Paper›PMID 26245169›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2016

Influence of allelic Variations of hypoxia-related and DNA repair genes on patient outcome and toxicity in head and neck cancer treated with radiotherapy plus cetuximab.

Carmen Muñoz, Miguel Caballero, Sofia Hakim, Eugenia Verger, Juan Jose Grau

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Carmen MuñozMolecular Oncology and Embryology Laboratory, Human Anatomy Unit, Medical School, University of Barcelona, Barcelona, Spain. carmen.munoz@ub.edu.
Miguel CaballeroOtolaryngology-Head and Neck Department-IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain. mcaba@clinic.ub.es.
Sofia HakimOtolaryngology-Head and Neck Department-IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain.
Eugenia VergerOtolaryngology-Head and Neck Department-IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain.
Juan Jose GrauOtolaryngology-Head and Neck Department-IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain.
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESUniversitat de Barcelona · ESHospital Clínic de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although cetuximab plus radiotherapy is a standard treatment for patients with inoperable head and neck squamous cell carcinoma (HNSCC), its efficacy varies greatly among individuals. To identify predictive markers of efficacy, we examined the effects of single nucleotide polymorphisms (SNPs) in hypoxia-related and DNA repair genes on the clinical outcome and occurrence of skin toxicity. We analyzed 61 consecutive patients with HNSCC for the presence of specific SNPs (HIF-1α, HIF-2α, HIF-1β, VHL, FIH-1, XRCC1, and XRCC5). The results were then correlated with time to progression (TTP), overall survival (OS), and toxicity (epithelitis, mucositis, and folliculitis). The median TTP and OS were better in patients with severe vs mild mucositis (17 vs 7 months, p = 0.03; and 26 vs 12 months, p = 0.016, respectively) and folliculitis (10 vs 7 months, p = 0.01, and 26 vs 10 months, p < 0.001, respectively). Patients with the HIF-1α CT/TT genotype had better OS than those with the wild-type HIF-1α CC genotype (28 vs 13 months, p = 0.035). Patients with the XRCC5 GG/AA genotype had longer TTP than patients with the XRCC5 AG genotype (11 vs 7 months, p = 0.035). Severe skin toxicity and SNPs of HIF-1α and XRCC5 were associated with different outcomes among patients treated with radiotherapy plus cetuximab.

Indexed as

AllelesCarcinoma, Squamous CellDNA RepairHead and Neck NeoplasmsPolymorphism, Single NucleotideAdultAgedAnalysis of VarianceAntineoplastic AgentsAryl Hydrocarbon Receptor Nuclear TranslocatorBasic Helix-Loop-Helix ProteinsCetuximabChemoradiotherapyDNA-Binding ProteinsEndothelial PAS Domain-Containing Protein 1FemaleAntineoplastic AgentsARNT protein, humanAryl Hydrocarbon Receptor Nuclear TranslocatorBasic Helix-Loop-Helix ProteinsCetuximabDNA-Binding ProteinsEndothelial PAS Domain-Containing Protein 1HIF1AN protein, humanHypoxia-Inducible Factor 1, alpha SubunitKu AutoantigenMixed Function OxygenasesRepressor ProteinsVon Hippel-Lindau Tumor Suppressor ProteinX-ray Repair Cross Complementing Protein 1XRCC1 protein, humanXRCC5 protein, humanCetuximabHead and neck squamous cell carcinomaRadiotherapySingle-nucleotide polymorphismToxicity

Identifiers

PMID26245169
OpenAlexW2103069476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.